Shares of bluebird bio Inc (NASDAQ:BLUE) have received an average rating of “Buy” from the nineteen ratings firms that are covering the firm. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $87.80.
Several equities research analysts have recently weighed in on the company. Jefferies Group LLC reiterated a “buy” rating and set a $88.00 price target on shares of bluebird bio in a research report on Friday, March 24th. Morgan Stanley upped their price objective on shares of bluebird bio from $58.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 1st. Maxim Group cut shares of bluebird bio from a “buy” rating to a “hold” rating and set a $87.00 price objective on the stock. in a research report on Monday, February 27th. They noted that the move was a valuation call. Roth Capital restated a “neutral” rating and issued a $71.00 price objective (down from $87.00) on shares of bluebird bio in a research report on Monday, February 6th. Finally, Zacks Investment Research cut shares of bluebird bio from a “buy” rating to a “hold” rating in a research report on Thursday, February 9th.
In other news, Director John Maraganore sold 13,839 shares of the stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $85.02, for a total transaction of $1,176,591.78. Following the completion of the sale, the director now owns 5,765 shares of the company’s stock, valued at $490,140.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director James Mandell sold 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 31st. The shares were sold at an average price of $75.04, for a total value of $600,320.00. Following the transaction, the director now owns 9,000 shares of the company’s stock, valued at approximately $675,360. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,694 shares of company stock valued at $3,859,704. Insiders own 3.50% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. First Mercantile Trust Co. acquired a new position in shares of bluebird bio during the third quarter worth approximately $129,000. Gradient Investments LLC acquired a new position in shares of bluebird bio during the third quarter worth approximately $333,000. Cupps Capital Management LLC acquired a new position in shares of bluebird bio during the third quarter worth approximately $1,824,000. Winslow Evans & Crocker Inc. increased its position in shares of bluebird bio by 170.0% in the third quarter. Winslow Evans & Crocker Inc. now owns 2,700 shares of the biotechnology company’s stock worth $183,000 after buying an additional 1,700 shares in the last quarter. Finally, Taylor Wealth Management Partners increased its position in shares of bluebird bio by 24,810.0% in the third quarter. Taylor Wealth Management Partners now owns 24,910 shares of the biotechnology company’s stock worth $1,688,000 after buying an additional 24,810 shares in the last quarter.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/04/21/analysts-set-bluebird-bio-inc-blue-pt-at-87-80-updated-updated.html.
Shares of bluebird bio (NASDAQ:BLUE) traded down 0.66% on Monday, reaching $82.45. 412,555 shares of the company traded hands. bluebird bio has a 52-week low of $35.37 and a 52-week high of $100.40. The stock’s market cap is $3.37 billion. The stock has a 50 day moving average of $87.79 and a 200 day moving average of $71.43.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, February 22nd. The biotechnology company reported ($1.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.86) by $0.02. bluebird bio had a negative net margin of 3,941.72% and a negative return on equity of 30.79%. The company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.76 million. During the same quarter in the prior year, the company earned ($1.29) earnings per share. The company’s quarterly revenue was up 5.4% on a year-over-year basis. On average, analysts expect that bluebird bio will post ($7.31) earnings per share for the current year.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.